Trial intelligence / Profile preview

Pyrotinib extended adjuvant therapy after trastuzumab for HER2-positive early or locally advanced breast cancer

CTR20191261Phase 3Active

Sponsor

Hengrui Therapeutics

Start

Jun 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1